Publications by authors named "Thomas Haidn"
Article Synopsis
- Immunotherapy, specifically ipilimumab, is a common treatment for metastatic melanoma, but finding reliable biomarkers to predict patient response remains a challenge, risking severe side effects.*
-
- A study showed that patients with a higher Body Mass Index (BMI) had significantly better responses to ipilimumab, as well as a lower likelihood of brain metastases compared to those with normal BMI.*
-
- While patients with a higher BMI tended to have longer overall survival rates, there were no significant differences in gender, T-stage, side effects, or progression-free survival between the BMI groups.*
